| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.025 |
| 52 Week High | kr0.075 |
| 52 Week Low | kr0.01 |
| Beta | 0.32 |
| 11 Month Change | -26.59% |
| 3 Month Change | 19.81% |
| 1 Year Change | -32.09% |
| 33 Year Change | -97.06% |
| 5 Year Change | n/a |
| Change since IPO | -96.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -3.2% | 0.09% |
| 1Y | -32.1% | -15.7% | 3.1% |
Return vs Industry: 6FN underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 6FN underperformed the German Market which returned 2.9% over the past year.
Price Volatility
| 6FN volatility | |
|---|---|
| 6FN Average Weekly Movement | 42.8% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6FN's share price has been volatile over the past 3 months.
Volatility Over Time: 6FN's weekly volatility (43%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
| 6FN fundamental statistics | |
|---|---|
| Market cap | €4.60m |
| Earnings (TTM) | -€3.76m |
| Revenue (TTM) | n/a |
-7.9x
P/S Ratio-1.2x
P/E RatioIs 6FN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FN income statement (TTM) | |
|---|---|
| Revenue | -kr6.53m |
| Cost of Revenue | kr0 |
| Gross Profit | -kr6.53m |
| Other Expenses | kr35.74m |
| Earnings | -kr42.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | 647.55% |
| Debt/Equity Ratio | 0% |
How did 6FN perform over the long term?
See historical performance and comparison